Diagnosis and Management of Female Sexual Arousal Disorder

  • Seth D. Cohen
  • Irwin GoldsteinEmail author


Women have more sexual health concerns in general than men, and women with sexual health problems have significant impairment of their life quality. Ironically, the study, diagnosis, and treatment of women with sexual health concerns are limited. One area with limited study is female sexual arousal disorder (FSAD), which is highly prevalent but often not well defined or understood. These women are the focus of this chapter. When assessing women with FSAD, it is important to address any predisposing factors that can exacerbate or alleviate symptoms. Both vaginal Doppler ultrasound and newer technologies like forward-looking infrared (FLIR) have been used to assess genital blood flow changes in the aroused and un-aroused states. Optimal therapy for FSAD depends on the etiology of the problem, and therapeutic options include medication adjustment, counseling and treatment of depression or anxiety, stress and fatigue reduction, sex therapy, and hormone replacement therapy. Androgens play an important role in healthy female sexual function, especially in stimulating sexual interest and in maintaining desire. Although no androgen therapies are currently approved by the Food and Drug Administration for FSAD, such therapies are used in clinical practice. In a comprehensive textbook on sexual health, it is important and appropriate to have a detailed chapter on the biology-focused management of FSAD. The basic premise of such management of FSAD is that the normal physiologic processes regulating sexual arousal are altered by biologic pathology. How each specific medical condition modulates female arousal requires additional investigation to elucidate.


Diagnosis Management Female sexual arousal disorder Forward-looking infrared 


  1. 1.
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Masters WH, Johnson VE. Human sexual response. Toronto: Bantam Books; 1966.Google Scholar
  3. 3.
    APA. Summary of practice-relevant changes to the DSM-IV-TR; 2000.Google Scholar
  4. 4.
  5. 5.
    Graham CA. The DSM diagnostic criteria for female sexual arousal disorder. Arch Sex Behav. 2009;39(2):240–55.CrossRefGoogle Scholar
  6. 6.
    Bancroft J. The endocrinology of sexual arousal. J Endocrinol. 2005;186:411–27.CrossRefPubMedGoogle Scholar
  7. 7.
    Singer B. Conceptualizing sexual arousal and attraction. J Sex Res. 1984;20:230–40.CrossRefGoogle Scholar
  8. 8.
    Graham CA, Sanders SA, Milhausen RR, McBride KR. Turning on and turning off: a focus group study of the factors that affect women’s sexual arousal. Arch Sex Behav. 2004;33(6):527–38.CrossRefPubMedGoogle Scholar
  9. 9.
    Bancroft J. Central inhibition of sexual response in the male: a theoretical perspective. Neurosci Biobehav Rev. 1999;23:763–84.CrossRefPubMedGoogle Scholar
  10. 10.
    Bancroft J, Janssen E. The dual control model of male sexual response: a theoretical approach to centrally mediated erectile dysfunction. Neurosci Biobehav Rev. 2000;24:571–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention. J Sex Med. 2015;12(1):189–97.CrossRefPubMedGoogle Scholar
  12. 12.
    Nappi RE, Martini E, Martella S, Capuano F, Bosoni D, Giacomini S, Beraghi M, Spinillo A. Maintaining sexuality in menopause. Post Reprod Health. 2014;20(1):22–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Bartlik B, Goldberg J. Female sexual arousal disorder. In: Leiblum SR, Rosen RC, editors. Principles and practice of sex therapy. 3rd ed. New York: Guilford; 2000. p. 85–117.Google Scholar
  14. 14.
    Levin RJ. The ins and outs of vaginal lubrication. Sex Relat Ther. 2003;18:509–13.CrossRefGoogle Scholar
  15. 15.
    Laan E, Everaerd W. Determinants of female sexual arousal: psychophysiological theory and data. Annu Rev Sex Res. 1995;6:32–76.Google Scholar
  16. 16.
    Sintchak G, Geer JH. A vaginal photoplethysmograph system. Psychophysiology. 1975;12:113–15.CrossRefPubMedGoogle Scholar
  17. 17.
    Everaerd W, Laan E, Both S, van der Velde J. Female sexuality. In: Szuchman L, Muscarella F, editors. Psychological perspectives on human sexuality. New York: Wiley; 2000. p. 108–22.Google Scholar
  18. 18.
    Huang FH, Zhang XL, Xiao LP, Xu YY, Zhang YZ. Study of blood flow improvement of topical application of estrogen on low genitourinary tract and its safety. Zhonghua Yi Xue Za Zhi. 2012;92(39):2778–80.PubMedGoogle Scholar
  19. 19.
    Dennerstein L, Burrows GD, Wood C, Hyman G. Hormones and sexuality: effect of estrogen and progestogen. Obstet Gynecol. 1980;56:316–22.PubMedGoogle Scholar
  20. 20.
    Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab. 1991;72:336–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Woodis CB, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy. 2012;32(1):38–53. doi: 10.1002/PHAR.1004.CrossRefPubMedGoogle Scholar
  22. 22.
    Chivers ML, Rosen RC. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? J Sex Med. 2010;7(2 Pt 2):858–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Afonso VM, Mueller D, Stewart J, Pfaus JG. Amphetamine pretreatment facilitates appetitive sexual behaviors in the female rat. Psychopharmacology (Berl). 2009;205(1):35–43.CrossRefGoogle Scholar
  24. 24.
    Afonso VM, Bablekis V, Pfaus JG. Sensory mediation of female-male mounting in the rat: II. Role of tactile and conspecific cues. Physiol Behav. 2006;87(5):863–9. Epub 2006 Feb 20.CrossRefPubMedGoogle Scholar
  25. 25.
    Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. Pharmacology of flibanserin. CNS Drug Rev. 2002;8(2):117–42.CrossRefPubMedGoogle Scholar
  26. 26.
    Jolly E, Clayton A, Thorp J, Lewis-D’Agostino D, Wunderlich G, Lesko L. Design of phase III pivotal trials of flibanserin in female hypoactive sexual desire disorder (HSDD). Sexologies. 2008;17 Suppl 1:S133–4.CrossRefGoogle Scholar
  27. 27.
    D'Aquila P, Monleon S, Borsini F, Brain P, Willner P. Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant. Eur J Pharmacol. 1997;340(2–3):121–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R. Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT1A receptors. Br J Pharmacol. 2003;139(7):1281–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6(6):1506–33.CrossRefPubMedGoogle Scholar
  30. 30.
    Allers K, Dremencov E, Ceci A, et al. Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study. J Sex Med. 2010;7(5):1757–67.CrossRefPubMedGoogle Scholar
  31. 31.
    Bremelanotide for organ protection and related indications, Palatin Technologies fact sheet. Retrieved 18 Jan 2009.Google Scholar
  32. 32.
    Palatin announces start of Bremelanotide Phase 3 program for female sexual dysfunction. PR Newswire. Retrieved 17 Feb 2015.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Advanced Urological CareNew YorkUSA
  2. 2.San Diego Sexual MedicineSan DiegoUSA

Personalised recommendations